NASDAQ:COYA Coya Therapeutics Q4 2025 Earnings Results & Report $4.34 +0.16 (+3.83%) Closing price 04:00 PM EasternExtended Trading$4.42 +0.09 (+1.96%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Coya Therapeutics missed analyst earnings expectations but beat on revenue in its Q4 2025 results, released March 16, 2026. The company reported EPS of -$0.34 versus the -$0.08 consensus estimate, while revenue of $3.96 million topped the $1.93 million estimate by $2.04 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 16, 2026TimeBefore Market Opens Coya Therapeutics EPS ResultsActual EPS-$0.34Consensus EPS -$0.08Beat/MissMissed by -$0.26One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersCoya Therapeutics Revenue ResultsActual Revenue$3.96 millionExpected Revenue$1.93 millionBeat/MissBeat by +$2.04 millionYoY Revenue GrowthN/AUpcoming EarningsCoya Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Coya Therapeutics Q4 2025 Earnings FAQ Did Coya Therapeutics beat earnings estimates for Q4 2025? Coya Therapeutics (NASDAQ:COYA) reported earnings of -$0.34 per share for Q4 2025, missing the consensus estimate of -$0.08. The report was announced on Monday, March 16, 2026. What was Coya Therapeutics' revenue for Q4 2025? Coya Therapeutics reported revenue of $3.96 million for Q4 2025, against a consensus estimate of $1.93 million. When is Coya Therapeutics' next earnings date? Coya Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Coya Therapeutics on the company's earnings history page. Coya Therapeutics Earnings HeadlinesCoya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALSOctober 14 at 1:44 PM | marketscreener.comMCoya Therapeutics, Inc. Plans to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALSOctober 14 at 1:44 PM | marketscreener.comMThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 15 at 1:00 AM | Investors Alley (Ad)Coya launches open-label ALS extension, reprioritizes pipelineOctober 14 at 9:11 AM | tipranks.comCoya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare ConferenceOctober 13 at 8:59 AM | finance.yahoo.comCoya Therapeutics, Inc. Completes Full Enrollment In Phase 2/3 ALSTARS Trial Of COYA 302 For The Treatment Of ALSOctober 6, 2026 | marketscreener.comMSee More Coya Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Coya Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coya Therapeutics and other key companies, straight to your email. Email Address About Coya TherapeuticsCoya Therapeutics (NASDAQ:COYA) is a clinical-stage biotechnology company focused on developing therapies that regulate neuroinflammation and support immune-system function. The company’s research centers on regulatory T cells, or Tregs, immune cells that help control excessive inflammatory responses. Coya is developing treatments intended for neurodegenerative diseases in which inflammation may contribute to disease progression. The company’s lead programs include COYA 101, an autologous Treg cell therapy in which a patient’s cells are collected, expanded and activated outside the body, and then administered as a potential treatment for amyotrophic lateral sclerosis (ALS). Coya is also developing combination approaches, including COYA 302, which is designed to combine Treg-based therapy with immune-modulating treatment. The company’s broader pipeline is intended to address additional neurodegenerative and inflammatory conditions. Coya Therapeutics is headquartered in Houston, Texas, and conducts its development activities through clinical research and collaborations with academic and medical institutions. Its programs remain investigational and are subject to clinical testing and regulatory review.View Coya Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
